Clinical Trials Directory

Trials / Terminated

TerminatedNCT02100150

A Safety and Efficacy Study of NNZ-2566 in Patients With Mild Traumatic Brain Injury (mTBI)

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of NNZ-2566 in the Acute Treatment of Adolescents and Adults With Mild Traumatic Brain Injury (mTBI)

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
32 (actual)
Sponsor
Neuren Pharmaceuticals Limited · Industry
Sex
All
Age
16 Years – 55 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of mTBI in adolescents and adults.

Detailed description

Traumatic brain injury (TBI) is an injury to the head caused by an external trauma that can lead to brain cell death, inflammation, edema, hemorrhage, and disruption of normal brain cell function. mTBI frequently results in persistent functional impairment including problems with cognitive function, memory, mood, and other personality disorders. There are currently no drugs available to reduce the brain damage or sequelae that result from TBI. Clearly, a safe and effective treatment for concussion injury and all forms of TBI would be an important development for military personnel as well as the general population. This study will investigate the safety and tolerability of treatment with oral administration of NNZ-2566 at 35 mg/kg or 70 mg/kg BID in adolescents and adults with mTBI. The study also will also investigate measures of efficacy during treatment.

Conditions

Interventions

TypeNameDescription
DRUGNNZ-2566Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (3g in 30 milliliter vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
DRUGPlaceboStrawberry flavored solution 0.5% v/v in Water for Injection

Timeline

Start date
2014-09-01
Primary completion
2016-06-01
Completion
2016-06-01
First posted
2014-03-31
Last updated
2018-02-05

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02100150. Inclusion in this directory is not an endorsement.